Mylan (NASDAQ:MYL) – Leerink Swann issued their FY2017 earnings per share (EPS) estimates for Mylan in a research report issued on Tuesday. Leerink Swann analyst A. Fadia anticipates that the company will post earnings of $4.55 per share for the year. Leerink Swann has a “Market Perform” rating and a $44.00 price objective on the stock. Leerink Swann also issued estimates for Mylan’s Q4 2017 earnings at $1.42 EPS, FY2018 earnings at $5.35 EPS, FY2019 earnings at $5.70 EPS, FY2020 earnings at $6.25 EPS and FY2021 earnings at $6.89 EPS.

Several other analysts have also recently issued reports on MYL. Citigroup reaffirmed a “buy” rating and issued a $58.00 price target (up from $48.00) on shares of Mylan in a report on Thursday. BMO Capital Markets reaffirmed a “buy” rating and issued a $45.00 price target on shares of Mylan in a report on Friday, September 29th. ValuEngine raised shares of Mylan from a “hold” rating to a “buy” rating in a report on Monday, October 2nd. Instinet reaffirmed a “buy” rating and issued a $37.00 price target on shares of Mylan in a report on Thursday, October 5th. Finally, Cowen reaffirmed a “market perform” rating and issued a $36.00 price target (up from $30.00) on shares of Mylan in a report on Thursday, October 5th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. Mylan presently has a consensus rating of “Buy” and a consensus target price of $43.20.

Shares of Mylan (NASDAQ:MYL) opened at $44.54 on Friday. The stock has a market cap of $23,770.00, a price-to-earnings ratio of 26.83, a P/E/G ratio of 1.44 and a beta of 1.38. The company has a quick ratio of 0.95, a current ratio of 1.46 and a debt-to-equity ratio of 1.05. Mylan has a twelve month low of $29.39 and a twelve month high of $45.87.

Mylan (NASDAQ:MYL) last posted its quarterly earnings results on Monday, November 6th. The company reported $1.10 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.20 by ($0.10). The company had revenue of $2.99 billion during the quarter, compared to analyst estimates of $3.09 billion. Mylan had a net margin of 7.28% and a return on equity of 20.63%. The company’s revenue was down 2.3% on a year-over-year basis. During the same period in the prior year, the company earned $1.38 earnings per share.

Several large investors have recently modified their holdings of MYL. Pzena Investment Management LLC grew its position in shares of Mylan by 84.1% during the third quarter. Pzena Investment Management LLC now owns 22,721,384 shares of the company’s stock worth $712,770,000 after acquiring an additional 10,381,697 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Mylan by 12.0% during the second quarter. Vanguard Group Inc. now owns 32,880,790 shares of the company’s stock worth $1,276,432,000 after acquiring an additional 3,531,974 shares during the last quarter. BlackRock Inc. grew its position in shares of Mylan by 4.5% during the second quarter. BlackRock Inc. now owns 40,574,158 shares of the company’s stock worth $1,575,089,000 after acquiring an additional 1,751,515 shares during the last quarter. Schroder Investment Management Group grew its position in shares of Mylan by 161,445.9% during the second quarter. Schroder Investment Management Group now owns 1,731,772 shares of the company’s stock worth $67,124,000 after acquiring an additional 1,730,700 shares during the last quarter. Finally, Teachers Advisors LLC grew its position in shares of Mylan by 72.2% during the second quarter. Teachers Advisors LLC now owns 3,346,814 shares of the company’s stock worth $129,923,000 after acquiring an additional 1,403,273 shares during the last quarter. 74.90% of the stock is currently owned by institutional investors.

WARNING: This report was originally posted by Watch List News and is owned by of Watch List News. If you are reading this report on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The original version of this report can be viewed at https://www.watchlistnews.com/mylan-myl-to-post-fy2017-earnings-of-4-55-per-share-leerink-swann-forecasts/1797653.html.

Mylan Company Profile

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.

Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with Analyst Ratings Network's FREE daily email newsletter.